<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03437733</url>
  </required_header>
  <id_info>
    <org_study_id>BWI_2017_01</org_study_id>
    <nct_id>NCT03437733</nct_id>
  </id_info>
  <brief_title>Multi-electrode Radiofrequency Balloon Catheter Use for the Isolation of the Pulmonary Veins.</brief_title>
  <acronym>SHINE</acronym>
  <official_title>Multi-electrode Radiofrequency Balloon Catheter Use for the Isolation of the Pulmonary Veins.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biosense Webster, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biosense Webster, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical investigation is a prospective, multicenter, single arm clinical evaluation
      utilizing the multi-electrode radiofrequency balloon catheter and the multi-electrode
      circular diagnostic catheter.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this clinical investigation is to assess the safety and acute effectiveness
      of the multi-electrode radiofrequency balloon catheter and multi-electrode circular
      diagnostic catheter when used for the isolation of the pulmonary veins in the treatment of
      Paroxysmal Atrial Fibrillation (PAF).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 28, 2018</start_date>
  <completion_date type="Actual">October 17, 2019</completion_date>
  <primary_completion_date type="Actual">February 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Early Onset Primary Adverse Events (PAEs)</measure>
    <time_frame>Up to 7 days (post initial mapping and ablation procedure)</time_frame>
    <description>PAEs included death, stroke/cerebrovascular accident or stroke (CVA), atrio-esophageal fistula, transient ischemic attack (TIA), myocardial infarction, phrenic nerve paralysis, cardiac tamponade/perforation, pulmonary vein stenosis, thromboembolism, major vascular access complication/bleeding.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Acute Procedural Success</measure>
    <time_frame>Day 1</time_frame>
    <description>Acute procedural success is defined as confirmation of entrance block in treated pulmonary veins (PV) after adenosine and/or isoproterenol challenge (with or without the use of a focal catheter).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">98</enrollment>
  <condition>Paroxysmal Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ablation with Multi-electrode Radiofrequency (RF) Balloon Catheter</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Radiofrequency Ablation</intervention_name>
    <description>RF ablation using multi-electrode radiofrequency balloon catheter and multi-electrode circular diagnostic catheter</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosed with Symptomatic Paroxysmal AF.

          2. Selected for atrial fibrillation (AF) ablation procedure for pulmonary vein isolation.

          3. Able and willing to comply with uninterrupted per-protocol anticoagulation
             requirements

          4. Age 18-75 years.

          5. Able and willing to comply with all pre-, post- and follow-up testing and
             requirements.

          6. Signed Patient Informed Consent Form.

        Exclusion Criteria:

          1. AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac
             cause.

          2. Previous surgical or catheter ablation for AF.

          3. Anticipated to receive ablation outside the PV ostia and Cavo-triscuspid-isthmus (CTI)
             region

          4. Previously diagnosed with persistent, longstanding AF and/or continuous AF &gt; 7 days,
             or &gt; 48 hrs terminated by cardioversion.

          5. Any percutaneous coronary intervention (PCI) within the past 2 months.

          6. Valve repair or replacement and presence of a prosthetic valve.

          7. Any carotid stenting or endarterectomy.

          8. Coronary artery bypass grafting (CABG), cardiac surgery (e.g. ventriculotomy,
             atriotomy), or valvular cardiac surgical or percutaneous procedure within the past 6
             months.

          9. Documented left atrium (LA) thrombus on baseline/pre-procedure imaging.

         10. LA antero posterior diameter &gt; 50 mm

         11. Any PV with a diameter â‰¥ 26 mm

         12. Left Ventricular Ejection Fraction (LVEF) &lt; 40%.

         13. Contraindication to anticoagulation (e.g. heparin).

         14. History of blood clotting or bleeding abnormalities.

         15. Myocardial infarction within the past 2 months.

         16. Documented thromboembolic event [including transient ischemic attack(TIA)] within the
             past 12 months.

         17. Rheumatic Heart Disease.

         18. Uncontrolled heart failure or New York Heart Association (NYHA) function class III or
             IV.

         19. Awaiting cardiac transplantation or other cardiac surgery within the next 12 months.

         20. Unstable angina.

         21. Acute illness or active systemic infection or sepsis.

         22. Diagnosed atrial myxoma or interatrial baffle or patch.

         23. Presence of implanted pacemaker or implantable cardioverter defibrillator (ICD).

         24. Significant pulmonary disease, (e.g. restrictive pulmonary disease, constrictive or
             chronic obstructive pulmonary disease) or any other disease or malfunction of the
             lungs or respiratory system that produces chronic symptoms.

         25. Significant congenital anomaly or medical problem that, in the opinion of the
             investigator, would preclude enrollment in this study.

         26. Women who are pregnant (as evidenced by pregnancy test if pre-menopausal), lactating,
             or who are of child bearing age and plan on becoming pregnant during the course of the
             clinical investigation.

         27. Enrollment in an investigational study evaluating another device, biologic, or drug.

         28. Has known pulmonary vein stenosis.

         29. Presence of intramural thrombus, tumor or other abnormality that precludes vascular
             access, or manipulation of the catheter.

         30. Presence of an Inferior Vena Cava (IVC) filter

         31. Presence of a condition that precludes vascular access.

         32. Life expectancy or other disease processes likely to limit survival to less than 12
             months.

         33. Presenting contra-indication for the devices (e.g. transthoracic echocardiography
             (TTE), CT, etc.) used in the study, as indicated in the respective instructions for
             use.

         34. Categorized as a vulnerable population and requires special treatment with respect to
             safeguards of well-being

             Additional exclusion criteria for Neurological Assessment Evaluable (NAE) subjects:

         35. Contraindication to use of contrast agents for MRI such as advanced renal disease,
             etc. (at PI discretion)

         36. Presence of iron-containing metal fragments in the body

         37. Unresolved pre-existing neurological deficit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Na Homolce Hospital</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;F. Miulli&quot;</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Cardiologico Monzino</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liverpool Heart and Chest Hospital</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bart's Health NHS Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Italy</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
  </removed_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>February 13, 2018</study_first_submitted>
  <study_first_submitted_qc>February 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2018</study_first_posted>
  <results_first_submitted>January 29, 2020</results_first_submitted>
  <results_first_submitted_qc>January 29, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 10, 2020</results_first_posted>
  <last_update_submitted>January 29, 2020</last_update_submitted>
  <last_update_submitted_qc>January 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Radiofrequency Ablation</keyword>
  <keyword>Paroxysmal Atrial Fibrillation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 20, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/33/NCT03437733/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 2, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/33/NCT03437733/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Roll-in Study Phase: RF Ablation</title>
          <description>Roll-in study phase was to demonstrate the acute effectiveness of the multi-electrode RF balloon catheter in the absence of confounding evidence that reflects early stages of a medical device learning curve.</description>
        </group>
        <group group_id="P2">
          <title>Main Study Phase: RF Ablation</title>
          <description>RF ablation was done using multi-electrode radiofrequency balloon catheter device (facilitate electrophysiological mapping of the heart and to transmit RF current to the target tissue) and multi-electrode circular diagnostic catheter device (recording and mapping of the atria of the heart with the carto system).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="90"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="87"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="87"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Eligibility criteria not met</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Population included all enrolled participants who have undergone insertion of the study catheter.</population>
      <group_list>
        <group group_id="B1">
          <title>Roll-in Study Phase: Radiofrequency (RF) Ablation</title>
          <description>Roll-in study phase was to demonstrate the acute effectiveness of the multi-electrode RF balloon catheter in the absence of confounding evidence that reflects early stages of a medical device learning curve.</description>
        </group>
        <group group_id="B2">
          <title>Main Study Phase: RF Ablation</title>
          <description>RF ablation was done using multi-electrode radiofrequency balloon catheter device (facilitate electrophysiological mapping of the heart and to transmit RF current to the target tissue) and multi-electrode circular diagnostic catheter device (recording and mapping of the atria of the heart with the carto system).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="87"/>
            <count group_id="B3" value="95"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                    <count group_id="B2" value="87"/>
                    <count group_id="B3" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.9" spread="6.90"/>
                    <measurement group_id="B2" value="60.2" spread="10.05"/>
                    <measurement group_id="B3" value="60.3" spread="9.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                    <count group_id="B2" value="87"/>
                    <count group_id="B3" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Early Onset Primary Adverse Events (PAEs)</title>
        <description>PAEs included death, stroke/cerebrovascular accident or stroke (CVA), atrio-esophageal fistula, transient ischemic attack (TIA), myocardial infarction, phrenic nerve paralysis, cardiac tamponade/perforation, pulmonary vein stenosis, thromboembolism, major vascular access complication/bleeding.</description>
        <time_frame>Up to 7 days (post initial mapping and ablation procedure)</time_frame>
        <population>The population analysis included the modified intent-to-treat (mITT) analysis set included all enrolled participants who met eligibility criteria, had undergone insertion of the study catheters and were followed-up for 90-days period for evaluation of PAEs.</population>
        <group_list>
          <group group_id="O1">
            <title>Radiofrequency (RF) Ablation</title>
            <description>RF ablation was done using multi-electrode radiofrequency balloon catheter device (facilitate electrophysiological mapping of the heart and to transmit RF current to the target tissue) and multi-electrode circular diagnostic catheter device (recording and mapping of the atria of the heart with the carto system).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Early Onset Primary Adverse Events (PAEs)</title>
          <description>PAEs included death, stroke/cerebrovascular accident or stroke (CVA), atrio-esophageal fistula, transient ischemic attack (TIA), myocardial infarction, phrenic nerve paralysis, cardiac tamponade/perforation, pulmonary vein stenosis, thromboembolism, major vascular access complication/bleeding.</description>
          <population>The population analysis included the modified intent-to-treat (mITT) analysis set included all enrolled participants who met eligibility criteria, had undergone insertion of the study catheters and were followed-up for 90-days period for evaluation of PAEs.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Acute Procedural Success</title>
        <description>Acute procedural success is defined as confirmation of entrance block in treated pulmonary veins (PV) after adenosine and/or isoproterenol challenge (with or without the use of a focal catheter).</description>
        <time_frame>Day 1</time_frame>
        <population>PP analysis set included participants who comply with the following criteria: a). were enrolled and met all eligibility criteria; b). had undergone RF ablation with study catheters; c) were treated for the study-related arrhythmia. Population included participants who had the adenosine/isoproterenol challenge.</population>
        <group_list>
          <group group_id="O1">
            <title>Radiofrequency (RF) Ablation</title>
            <description>RF ablation was done using multi-electrode radiofrequency balloon catheter device (facilitate electrophysiological mapping of the heart and to transmit RF current to the target tissue) and multi-electrode circular diagnostic catheter device (recording and mapping of the atria of the heart with the carto system).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Acute Procedural Success</title>
          <description>Acute procedural success is defined as confirmation of entrance block in treated pulmonary veins (PV) after adenosine and/or isoproterenol challenge (with or without the use of a focal catheter).</description>
          <population>PP analysis set included participants who comply with the following criteria: a). were enrolled and met all eligibility criteria; b). had undergone RF ablation with study catheters; c) were treated for the study-related arrhythmia. Population included participants who had the adenosine/isoproterenol challenge.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 6 months</time_frame>
      <desc>The safety population included all participants who have undergone insertion of the study catheter.</desc>
      <group_list>
        <group group_id="E1">
          <title>Roll-in Study Phase: RF Ablation</title>
          <description>Roll-in study phase was to demonstrate the acute effectiveness of the multi-electrode RF balloon catheter in the absence of confounding evidence that reflects early stages of a medical device learning curve.</description>
        </group>
        <group group_id="E2">
          <title>Main Study Phase: RF Ablation</title>
          <description>RF ablation was done using multi-electrode radiofrequency balloon catheter device (facilitate electrophysiological mapping of the heart and to transmit RF current to the target tissue) and multi-electrode circular diagnostic catheter device (recording and mapping of the atria of the heart with the carto system).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 20.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Major Vascular Access Complication/ Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Franchise Medical Director</name_or_title>
      <organization>Biosense Webster, Inc.</organization>
      <phone>844-434-4210</phone>
      <email>ClinicalTrialDisclosure@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

